SciTech Presenting at Annual American Society of Hematology Meeting (ASH 2019)
SciTech will be presenting its ST-001 nanoFenretinide technology, which is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of fenretinide in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes fenretinide formulations for the treatment of several cancer indications.
The poster presentation highlights SciTech's proposed clinical trial titled "A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma". An abstract of the presentation will be published online in the November 2019 supplemental issue of Blood.
The company has submitted an Investigational New Drug (IND) Application for ST-001 nanoFenretinide and the FDA has granted it Orphan Drug Status for the treatment of two types of non-Hodgkin's lymphoma (NHL): peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Information regarding SciTech's nano formulation technology and oncology drug product ST-001 nanoFenretinide is available from SciTech Development, LLC by calling +1-313-938-5517 or online at https://www.scitechdevelopment.com/
About SciTech Development
SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | firstname.lastname@example.org
About the American Society of Hematology (ASH)
ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. More information regarding ASH can be found online at https://www.hematology.org/
For More Information About SciTech
Earle T. Holsapple, President
SciTech Development, LLC
This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties.
Louis M. Scarmoutzos, Ph.D.